Immunogenicity in Biosimilars: Why Immune Responses May Differ from Reference Biologics

When you hear the word biosimilar, you might think it’s just like a generic drug - cheaper, same effect, done. But that’s not true. Biosimilars aren’t chemically identical like your everyday generic pills. They’re made from living cells - human or animal - and even tiny changes in how those cells are grown can change how your body reacts. One of the biggest concerns? Immunogenicity. That’s the fancy term for when your immune system sees the drug as a threat and starts fighting back.

What Is Immunogenicity, Really?

Immunogenicity means your body produces antibodies against the drug. These aren’t normal antibodies that fight colds or flu. These are called anti-drug antibodies (ADAs). They stick to the biologic, like a lock on a key, and can block it from working. In some cases, they can even cause serious reactions - think rashes, swelling, or worse, anaphylaxis.

It sounds scary, but here’s the catch: even the original biologic drugs - the ones biosimilars are copying - can cause this. For example, about 70% of patients on some monoclonal antibodies develop ADAs over time. So the real question isn’t whether immunogenicity happens. It’s: Does the biosimilar cause more of it than the original?

Why Can’t Biosimilars Be Exactly the Same?

Think of a biologic like a complex sculpture made of clay. The original is hand-sculpted by one artist. A biosimilar is made by another artist using the same blueprint, but different tools, different clay, maybe even different weather in the studio. The final shape looks identical. But under a microscope? Tiny differences show up.

These differences come from:

• Post-translational modifications - things like sugar chains (glycans) attached to the protein. A small change in sialylation or galactosylation can alter how the immune system sees the drug.
• Manufacturing impurities - leftover proteins from the host cells (like Chinese hamster ovary cells). If there’s more than 100 parts per million, ADA risk jumps by 87%.
• Protein aggregates - clumps of the drug that form during storage or handling. If they make up more than 5% of the product, immunogenicity risk triples.
• Stabilizers - one biosimilar might use polysorbate 80; the original uses polysorbate 20. Sounds minor? It’s not. These can change how the protein folds and whether it clumps.

These aren’t bugs - they’re expected. But they’re why regulators demand head-to-head testing. You can’t just say, “It’s close enough.” You have to prove it’s the same in how your body responds.

How Do We Measure Immune Response?

Testing for ADAs isn’t as simple as a blood test. It’s a three-step process:

1. Screening - Does the patient have any antibodies at all?
2. Confirmation - Are those antibodies really targeting the drug, or is it a false positive?
3. Characterization - Are they neutralizing? That means they block the drug from working.

And here’s the problem: the method matters. One lab might use electrochemiluminescence (ECL) and find 13.1% of patients developed ADAs. Another lab using ELISA might only find 5%. If you compare a biosimilar tested with one method to the original tested with another, you’re not comparing apples to apples - you’re comparing apples to oranges.

That’s why the EMA and FDA both say: comparative studies must use identical assays. Same equipment. Same reagents. Same timing. Otherwise, you’re not measuring immunogenicity - you’re measuring lab technique.

What Makes Some People More Likely to React?

It’s not just about the drug. Your body matters too.

• Route of delivery - Shots under the skin (subcutaneous) cause 30-50% more ADAs than IV infusions. That’s why some biosimilars - like those for rheumatoid arthritis - are designed for injection.
• How often you take it - If you get the drug every 2 weeks, your immune system has less time to adapt. Continuous dosing lowers risk by 25% compared to intermittent use.
• Your genes - People with the HLA-DRB1*04:01 gene variant are nearly 5 times more likely to develop ADAs to certain biologics.
• Your disease - Patients with rheumatoid arthritis have 2.3 times higher risk than healthy people. Why? Their immune systems are already on high alert.
• Other drugs - Taking methotrexate with a TNF inhibitor cuts ADA rates by 65%. That’s why combo therapy is standard in autoimmune diseases.

So even if two biosimilars are identical on paper, one might cause more reactions in a patient with RA who’s not on methotrexate. Context is everything.

Real-World Evidence: What Do Patients Actually Experience?

Let’s cut through the noise. What do real patients and real studies say?

In 2021, a study of 1,247 rheumatoid arthritis patients found no difference in ADA rates between the original infliximab and its biosimilar CT-P13. Both had around 12% ADA incidence. That’s reassuring.

But then came the NOR-SWITCH trial. 481 patients switched from the original infliximab to the biosimilar. The biosimilar group had slightly higher ADA rates - 11.2% vs. 8.5%. Still, no difference in clinical outcomes. No more flares. No more hospital visits.

Then there’s adalimumab. The Danish Biologics Registry found that Humira (the original) had 18.7% ADA rates. Amgevita (the biosimilar) had 23.4%. Statistically significant? Yes. Clinically meaningful? Not really. Patients still responded well. No drop in effectiveness.

And then there are the Reddit threads.

One patient, u/RheumPatient87, wrote: “After switching to the biosimilar etanercept, I got red, itchy injection sites. Never happened with the original.” Another, u/BiologicSurvivor, said: “Switched to biosimilar rituximab three years ago. Zero difference.”

Surveys of rheumatologists tell a similar story. 68% think immunogenicity fears are overblown. 22% say they’ve seen real differences in practice. That’s a wide gap. It means some doctors see it. Some don’t. And the patients? They’re the ones living with it.

Regulators Are Watching - But What Do They Require?

The FDA and EMA don’t just say, “Make it similar.” They demand proof. Here’s what’s required:

• Analytical similarity - The biosimilar must match the original in structure, purity, and function at a molecular level.
• Animal studies - Toxicity and pharmacokinetics must be comparable.
• Clinical trials - Head-to-head studies in a sensitive population (like RA or psoriasis) to prove safety and efficacy.
• Immunogenicity testing - Must be done with the same assays, same timing, same patient population.

And they’re not done. The FDA’s “totality of evidence” approach means they look at everything - from manufacturing to patient outcomes. If one biosimilar has higher ADA rates but no drop in effectiveness, it can still be approved. The bar isn’t zero immunogenicity. It’s no clinically meaningful difference.

What Does This Mean for Patients?

Here’s the bottom line:

• Yes, biosimilars can trigger immune responses - just like the originals.
• Minor differences exist, but they rarely lead to real-world problems.
• Most patients switch without issue.
• If you notice new side effects after switching - redness, swelling, fever, fatigue - tell your doctor. It’s rare, but it happens.
• Don’t assume biosimilars are risk-free. But don’t fear them either.

What’s more important? Cost. Biologics can cost $30,000-$70,000 a year. Biosimilars? Often half that. For many patients, that’s the difference between staying on treatment and stopping.

The Future: Smarter Testing, Fewer Surprises

Experts predict that by 2027, we’ll be able to map the exact sugar chains on a biologic molecule with 99.5% accuracy using advanced mass spectrometry. That means we’ll know not just if two drugs are similar - but why they’re similar.

Some labs are already combining proteomics (protein shapes), glycomics (sugar patterns), and immunomics (immune reactions) to predict risk before a drug even hits the market. It’s like a weather forecast for your immune system.

And the data keeps growing. In Europe, 85% of infliximab prescriptions are now biosimilars. In the U.S., adoption is slower - but rising. As more patients use them and more studies are done, the fear fades. The science catches up.

Immunogenicity isn’t going away. But we’re learning how to manage it - not avoid it.